ClinicalTrials.gg
RecruitingNCT07286266Updated Oct 15, 2026

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

A Phase 3 interventional study of Mocertatug rezetecan and Paclitaxel in Ovarian Neoplasms, sponsored by GlaxoSmithKline. Recruiting at 22 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 15, 2026First sites in South Korea and United KingdomPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Ovarian Neoplasms by GlaxoSmithKline — 5 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · GlaxoSmithKline.

Planned enrollment
7th of 30
450 · median 77
Started
2026
with 2 others
Phase 3
7 of 31
3 open now
Registered
29th of 31
by date

Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 7th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 3, and was the 29th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 31 studies in Ovarian Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Ovarian Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

Keywords

  • Platinum-resistant Ovarian Cancer
  • Mocertatug rezetecan
  • Mo-Rez
  • GSK5733584
  • Paclitaxel
  • Pembrolizumab
  • Bevacizumab
  • Pegylated liposomal doxorubicin (PLD)
  • Topotecan
  • Gemcitabine
  • Antibody-drug conjugate
  • BEHOLD-Ovarian01
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Form (ICF).
  • Has epithelial ovarian cancer, inclusive of primary peritoneal or fallopian-tube cancer with a confirmed diagnosis of high grade serous, high grade endometrioid, or clear cell carcinoma, or carcinosarcoma that is resistant to platinum-based therapy.

Platinum-resistance is defined as follows:

  • Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum therapy, must have had a response (CR, PR, stable disease) and then progressed from >3 months to ≤6 months after the last dose of platinum therapy.
  • Participants who have received >1 line of platinum therapy must have progressed on or ≤6 months after the date of the last dose of platinum therapy.

    • Has received at least 1 but no more than 4 prior lines of systemic anti-cancer therapy. are defined as follows:
  • Adjuvant ± are considered one line of therapy.
  • Maintenance therapy (e.g., bevacizumab, [poly adenosine diphosphate-ribosylation (ADP) ribose polymerase inhibitor (PARPi)] will be considered as part of the preceding line of therapy (i.e., not counted independently).
  • Therapy changed to another agent in the same class due to toxicity in the absence of progression will be considered as part of the same line of therapy (i.e., not counted independently).
  • Unplanned addition or switching to a new drug in a different class is considered a separate line of therapy.
  • Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance.

    • Must have received prior treatment with the following therapies unless they have a per label or institutional guidelines as described below:
  • Mirvetuximab soravtansine (MIRV),.
  • The tumor demonstrates positive folate receptor alpha FRα expression (≥ 75% of viable tumor cells with moderate (2+) and/or strong (3+) membrane staining) per a test compliant to local regulation, AND
  • Does not have a documented contraindication per label or local institutional guidelines, including but not limited to chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, monocular vision, peripheral neuropathy, interstitial lung disease, or . AND
  • It is available in the enrolment country. A regimen is considered available if it is approved and reimbursed (covered by national healthcare or private insurance) in the participating country.
  • Bevacizumab, unless the participant has a documented contraindication per label or local institutional guidelines. Contraindications include but are not limited to vascular disorders (uncontrolled hypertension, arterial thromboembolic events), fistula, gastro-intestinal disorders (rectosigmoid involvement, bowel obstruction), delayed wound healing, bleeding diathesis (haemoptysis, epistaxis, pulmonary haemorrhage, acquired coagulopathy), nephrotic syndrome or significant proteinuria, or osteonecrosis of the jaw, or hypersensitivity
  • PARPi, in participants with known or suspected deleterious germline or somatic BRCA mutations and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase PARPi as maintenance treatment, if a PARPi is available in the enrolment country, unless the participants is not eligible for treatment with PARPi. A regimen is considered available if it is approved and reimbursed (covered by national healthcare or private insurance) in the participating country.

    • Has at least one Target lesion (TL) per 1.1, as determined by the investigator. that have been previously irradiated and have been shown to be progressing following irradiation may be considered as TLs.
    • Has provided a Formalin fixed, paraffin embedded (FFPE) tumor tissue sample of sufficient quantity and quality for the central assessment of B7 homolog 4 protein (B7-H4) expression, with B7-H4 expression result available prior to date of randomization.

AND

  • FR alpha expression
  • In countries where mirvetuximab is available, an FR alpha expression result from a test compliant with local regulation or by central testing is required to determine eligibility.
  • In countries where mirvetuximab is unavailable, an FFPE tumor tissue sample confirmed to be of sufficient quantity and quality must be provided. The FR alpha expression result is not required prior to randomisation or to determine eligibility.

AND

  • expression, where a result from a local test is NOT available, an FFPE tumor tissue sample confirmed to be of sufficient quantity and quality must be provided. The PD-L1 expression result is not required prior to randomisation or to determine eligibility.

    • Is eligible to receive 1 of the standard of care interventions if randomized to physician's choice arm.
    • A female participant is eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:
  • Is a Participant of non- (PONCBP) OR
  • Is a Participant of childbearing potential (POCBP) and using a method that is highly effective (with a failure rate of \<1% per year), with low user dependency, 30 days prior to Cycle 1 Day 1 (C1D1) and during the study intervention period and for at least 8 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.

    • A POCBP must have a negative, highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention
  • If a urine test is positive or ambiguous and cannot be confirmed as negative, a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

    • Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the study protocol.
    • Has an (ECOG) performance status of 0 or 1.
    • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has primary platinum- Ovarian Cancer (OC), defined as disease that did not respond to or has progressed within \<3 months of the final dose of platinum containing chemotherapy.
  • Has a (except disease under study) that has progressed or required active treatment within 36 months prior to date of randomization, except for basal cell or squamous cell carcinomas of the skin, in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of disease, or that is otherwise considered cured by the investigator.
  • Has known sensitivity to study intervention components or or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
  • Has untreated brain or or brain/CNS metastases that have progressed (e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain/CNS metastases). Participants with previously treated and clinically stable brain/CNS metastases and who have completed all therapy for ≥14 days prior to date of C1D1 are not excluded from participation.
  • Has any evidence of current ILD or pneumonitis, or a prior history of ILD or non-infectious pneumonitis.
  • Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy, excluding e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy, or that the investigator, with the agreement of the sponsor, considers to be not for the tolerability of study intervention in the current clinical study.
  • Has any serious and/or unstable medical condition (including infection) or any serious and/or unstable psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of , or compliance to the study procedures, including requirements for the Follow-up Period of the study.
  • For participants selected to receive the pembrolizumab-containing regimen as the intended physician's choice only: Has experienced any of the following with prior immunotherapy-any immune-mediated adverse event (imAE) ≥ Grade 3, immune-mediated severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade (Stevens-Johnson Syndrome [SJS], Toxic Epidermal Necrolysis [TEN], or drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome), or myocarditis of any grade
  • For participants selected to receive bevacizumab as part of the pembrolizumab + paclitaxel ± bevacizumab intended physician's choice regimen only: Has a history of vascular disorders (uncontrolled hypertension, arterial thromboembolic events), fistula, gastro-intestinal disorders (rectosigmoid involvement, bowel obstruction), delayed wound healing, bleeding diathesis (hemoptysis, epistaxis, pulmonary hemorrhage, acquired coagulopathy), nephrotic syndrome or significant proteinuria, or osteonecrosis of the jaw, or .
  • Has had any major surgery within 28 days prior to date of C1D1 or received focal radiotherapy within 21 days prior to date of C1D1.
  • Has received treatment with an agent within 30 days prior to date of C1D1.
  • Has received treatment with any cytotoxic chemotherapy drugs or other anti-tumor drugs (including endocrine therapy, molecular targeted therapy, immunotherapy, biotherapy, or investigational agent) within 30 days or 5 half-lives, whichever is shorter, prior to date of C1D1; or need to continue these drugs during study participation.
  • Has ever received prior therapy with topoisomerase I inhibitors (e.g., topotecan) or ADC with a topo1i payload, or B7-H4 targeted therapy.
  • Has received any within 30 days prior to date of C1D1.
  • Has received any transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days prior to date of C1D1.
  • For participants receiving PLD only: Has baseline (LVEF) \<50% or lower than institutional lower limits of normal. Intolerance to PLD does not exclude a participant from the study if a different physician's choice option is chosen prior to randomization.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Mocertatug rezetecan

    Participants will receive Mocertatug rezetecan

    Drug: Mocertatug rezetecan

  • Active comparator
    Standard of care

    Participants will receive standard of care chemotherapy (Paclitaxel or Pembrolizumab + paclitaxel ± bevacizumab or PLD or Topotecan or Gemcitabine) as per investigator's choice

    Drug: Paclitaxel · Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Topotecan · Drug: Gemcitabine · Drug: Pembrolizumab · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by BICR

    PFS is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first.

    Time frame: Up to approximately 212 weeks

  2. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause

    Time frame: Up to approximately 212 weeks

Secondary outcomes

  1. PFS by investigator assessment

    PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first

    Time frame: Up to approximately 212 weeks

  2. Objective response rate (ORR) by BICR

    ORR is defined as the percentage of participants with best overall response of either complete response (CR) or partial response (PR) per RECIST 1.1 by BICR assessment

    Time frame: Up to approximately 212 weeks

  3. Duration of Response (DOR) by BICR

    DOR is defined as the time from the date of first documented objective response (CR or PR) per RECIST 1.1 by BICR assessment to the date of first documented Progressive Disease (PD) per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first

    Time frame: Up to approximately 212 weeks

  4. ORR by investigator assessment

    ORR is defined as the percentage of participants with best overall response of either CR or PR per RECIST 1.1 by investigator assessment

    Time frame: Up to approximately 212 weeks

  5. DOR by investigator assessment

    DOR is defined as the time from the date of first documented objective response (CR or PR) per RECIST 1.1 by investigator assessment to the date of first documented PD per RECIST 1.1 by investigator assessment or death due to any cause, whichever occurs first

    Time frame: Up to approximately 212 weeks

  6. PFS2

    PFS2 is defined as the time from the date of randomization to the date of first documented investigator-assessed clinical or radiographical progression following the first subsequent anticancer therapy and after the progression event used for PFS, or death from any cause, whichever occurs first

    Time frame: Up to approximately 212 weeks

  7. Number of participants with Treatment-emergent adverse event (TEAEs), Adverse event of special interest (AESIs) and Treatment-emergent serious adverse event (TESAEs)

    Time frame: Up to approximately 212 weeks

  8. Number of participants with TEAEs/AESI/TESAEs leading to dose modifications or study intervention discontinuation

    Time frame: Up to approximately 212 weeks

  9. Number of participants with changes in vital signs, laboratory tests (hematology and clinical chemistry), and Electrocardiogram (ECG)

    Time frame: Up to approximately 212 weeks

  10. Serum concentration of Mo-Rez (conjugated antibody and free payload)

    Time frame: Up to approximately 212 weeks

  11. Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Mo-Rez

    Time frame: Up to approximately 212 weeks

  12. Titers of ADA against Mo-Rez

    Time frame: Up to approximately 212 weeks

  13. Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score

    The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. The following domains will be measured: Global health status (GHS)/ Quality of Life (QoL), physical functioning, role functioning Participants responses on these items are . averaged and then transformed to scores . ranging from 0 to 100. Higher . score indicates better functioning or a better . overall state of health.

    Time frame: Up to approximately 212 weeks

  14. Change from baseline in EORTC QLQ-Ovarian Cancer Module (OV28) score

    The EORTC QLQ-OV28 includes a 28-item questionnaire for evaluating ovarian cancer-specific symptoms and concerns in participants of cancer clinical studies. These include items that assess symptoms in the abdominal/gastrointestinal domain. Scores are averaged and transformed to a 0 to 100 scale; higher scores indicate a greater symptom burden, while lower scores reflect fewer symptoms.

    Time frame: Up to approximately 212 weeks

  15. Time to deterioration (TTD) of EORTC QLQ-OV28

    TTD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on the abdominal/gastrointestinal symptom domain of the EORTC QLQ-OV28

    Time frame: Up to approximately 212 weeks

  16. TTD of EORTC QLQ-C30

    TTD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on any of the following EORTC QLQ-C30 domains: physical functioning, role functioning and Global Health Status (GHS)/ Quality of Life (QoL).

    Time frame: Up to approximately 212 weeks

  17. Maximum Post-baseline Patient-reported outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) Score

    The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicities in participants in cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. A subset of items selected from the PRO-CTCAE item library will be assessed. This measure captures maximum post-baseline PRO-CTCAE score for each frequency, severity and/or interference of symptomatic AEs

    Time frame: Up to approximately 212 weeks

  18. CA-125 response rate as per Gynecologic Cancer InterGroup (GCIG) criteria.

    Percentage of participants with a CA-125 response will be assessed

    Time frame: Up to approximately 212 weeks

07

Study locations

22 of 22 sites recruiting
  • GSK Investigational Site
    Randwick, New South Wales 2031, Australia
    Recruiting
  • GSK Investigational Site
    Auchenflower, Queensland 4066, Australia
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 1Z5, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H2X 0C1, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • GSK Investigational Site
    Fukuoka, 811-1395, Japan
    Recruiting
  • GSK Investigational Site
    Fukuoka, 830-0011, Japan
    Recruiting
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
    Recruiting
  • GSK Investigational Site
    Hyōgo, 673-8558, Japan
    Recruiting
  • GSK Investigational Site
    Kanagawa, 216-8511, Japan
    Recruiting
  • GSK Investigational Site
    Kanagawa, 241-8515, Japan
    Recruiting
  • GSK Investigational Site
    Mie, 514-8507, Japan
    Recruiting
  • GSK Investigational Site
    Okinawa, 901-2725, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 569-8686, Japan
    Recruiting
  • GSK Investigational Site
    Saitama, 350-1298, Japan
    Recruiting
  • GSK Investigational Site
    Tottori, 683-8504, Japan
    Recruiting
  • GSK Investigational Site
    Seoul, Seoul Teugbyeolsi 06351, South Korea
    Recruiting
  • GSK Investigational Site
    Gyeonggi-do, 10408, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 03722, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 05505, South Korea
    Recruiting
  • GSK Investigational Site
    Suwon Kyunggi-do, 443-380, South Korea
    Recruiting
  • GSK Investigational Site
    London, NW1 2BU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2030, 49 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 49 months is close to that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Dec 2029 → Jul 2030 and completion Dec 2029 → Jul 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Dec 16, 2025
StartActual
Jun 18, 2026
Primary completionEst.
Jul 22, 2030was Dec 2029
CompletionEst.
Jul 22, 2030was Dec 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
17 sites added — first sites in South Korea and United Kingdom
Show 17 added (9 Japan, 5 South Korea, 1 Australia, 1 Canada, 1 United Kingdom)
  • GSK Investigational Site · Auchenflower, Australia
  • GSK Investigational Site · Toronto, Canada
  • GSK Investigational Site · Fukuoka, Japan
  • GSK Investigational Site · Fukuoka, Japan
  • GSK Investigational Site · Hokkaido, Japan
  • GSK Investigational Site · Kanagawa, Japan
  • GSK Investigational Site · Kanagawa, Japan
  • GSK Investigational Site · Mie, Japan
  • GSK Investigational Site · Okinawa, Japan
  • GSK Investigational Site · Saitama, Japan
  • GSK Investigational Site · Tottori, Japan
  • GSK Investigational Site · Seoul, South Korea
  • GSK Investigational Site · Gyeonggi-do, South Korea
  • GSK Investigational Site · Seoul, South Korea
  • GSK Investigational Site · Seoul, South Korea
  • GSK Investigational Site · Suwon Kyunggi-do, South Korea
  • GSK Investigational Site · London, United Kingdom
Oct 2, 2026
Primary completion
Dec 17, 2029→Jul 22, 2030
Oct 15, 2026
Study completion
Dec 17, 2029→Jul 22, 2030
Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    Primary completion Dec 17, 2029→Jul 22, 2030
    Study completion Dec 17, 2029→Jul 22, 2030
    + 1 other change: verification date
  2. Oct 2, 2026
    17 sites added — first sites in South Korea and United Kingdom
    Show 17 added (9 Japan, 5 South Korea, 1 Australia, 1 Canada, 1 United Kingdom)
    • GSK Investigational Site · Auchenflower, Australia
    • GSK Investigational Site · Toronto, Canada
    • GSK Investigational Site · Fukuoka, Japan
    • GSK Investigational Site · Fukuoka, Japan
    • GSK Investigational Site · Hokkaido, Japan
    • GSK Investigational Site · Kanagawa, Japan
    • GSK Investigational Site · Kanagawa, Japan
    • GSK Investigational Site · Mie, Japan
    • GSK Investigational Site · Okinawa, Japan
    • GSK Investigational Site · Saitama, Japan
    • GSK Investigational Site · Tottori, Japan
    • GSK Investigational Site · Seoul, South Korea
    • GSK Investigational Site · Gyeonggi-do, South Korea
    • GSK Investigational Site · Seoul, South Korea
    • GSK Investigational Site · Seoul, South Korea
    • GSK Investigational Site · Suwon Kyunggi-do, South Korea
    • GSK Investigational Site · London, United Kingdom
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07286266
Lead sponsor
GlaxoSmithKline
Collaborators
GOG, ENGOT, APGOT
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Jun 18, 2026
Primary completion
Jul 22, 2030 (estimated)
Completion
Jul 22, 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mocertatug rezetecan

Start the discussion